Pfizer (NYSE:PFE) Upgraded by Hsbc Global Res to Strong-Buy Rating

Hsbc Global Res upgraded shares of Pfizer (NYSE:PFE) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Wednesday. Finally, Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Down 1.0 %

Shares of NYSE PFE opened at $25.73 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer has a 52 week low of $24.48 and a 52 week high of $31.54. The stock has a market capitalization of $145.79 billion, a P/E ratio of 18.24, a PEG ratio of 0.64 and a beta of 0.61. The stock’s fifty day moving average is $26.28 and its 200 day moving average is $27.18.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the business earned $0.10 earnings per share. Pfizer’s revenue was up 24.7% on a year-over-year basis. Sell-side analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is owned by insiders.

Hedge Funds Weigh In On Pfizer

Hedge funds and other institutional investors have recently made changes to their positions in the stock. PSI Advisors LLC increased its holdings in Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 385 shares in the last quarter. Waddell & Associates LLC increased its holdings in Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock worth $723,000 after purchasing an additional 388 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its holdings in Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares in the last quarter. D Orazio & Associates Inc. increased its holdings in Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares in the last quarter. Finally, Lipe & Dalton increased its holdings in Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 400 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.